Term
What is the most common chronic inflammation? |
|
Definition
|
|
Term
|
Definition
invasive region of the snyovium that erodes into cartiledge and bone |
|
|
Term
What type of immunoglobins are usually present in RA? and which is associated with higher systemic complications |
|
Definition
1) usually IgM 2) IgG associated with systemic complications |
|
|
Term
What is clinical manifestation characteristic of most RA patients? |
|
Definition
stiffness, especially in the AM which lasts for >30 min. |
|
|
Term
people with RA have an increased risk for what? |
|
Definition
malignancy: lymphoma, luekemia, multiple myeloma |
|
|
Term
What is a common manifestation of RA in hands outside of joint swelling |
|
Definition
|
|
Term
What is common manifestation of the elbow and shoulders |
|
Definition
synovitis of the elbow joint and inflammation and nodules in the olecranon bursa |
|
|
Term
What part of the spine is involved in RA? |
|
Definition
|
|
Term
What is the most common extra-articular manifestation of RA? |
|
Definition
Rheumatoid nodules - areas exposed to pressure |
|
|
Term
What is the most frequent ocular manifestation of RA? |
|
Definition
|
|
Term
What is the most common lung manifestation? |
|
Definition
pleurisy with effusion-RF usually present |
|
|
Term
|
Definition
RA with splenomegaly, leukopenia, and skin ulcers |
|
|
Term
What is a vascular hallmark of early RA? |
|
Definition
vasculitis in small synovial vessels |
|
|
Term
What is the most specific test for RA? What is the most sensitive test for RA? |
|
Definition
1) specific CCP antibodies 2) sensitive RF antibodies |
|
|
Term
synovial fluid findings in RA? |
|
Definition
1) straw-colored, turbid 2) neutrophils 3) low/normal glucose levels |
|
|
Term
|
Definition
Start with NSAIDS, rapidly add methotrexate, add-on sulfasalazine, antimalarial, leflunomide, and TNF inhibitor |
|
|
Term
What is the most pharamcologic treatment for RA? |
|
Definition
|
|
Term
What is the MOA of abatacept and rituximab |
|
Definition
biological agents 1) abatacept: blocks T cell activation 2) rituximab: B cell targeted therapy |
|
|